Safety analysis of weekly paclitaxel plus S-1 versus paclitaxel plus 5-fluorouracil/calcium folinate as first-line therapy in advanced gastric cancer: a multicenter open random phase II trial
Ting Deng(Tianjin Medical University Cancer Institute and Hospital), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Yan Zhao(Beijing University of Chinese Medicine), Yang Yao(University of Science and Technology of China), Jianping Xiong(Nanchang University), Yang Zhang(North China University of Water Resources and Electric Power), Zhuang Yu(Shanghai East Hospital), Rong-Sheng Zheng(First Affiliated Hospital of Bengbu Medical College), Zengqing Guo(Fujian Provincial Cancer Hospital), Chun-Hong Hu(Central South University), Zhi-Xiang Zhuang(Soochow University), Hui-Ping Wan(Jiangxi Provincial People's Hospital), Ding-Zhi Huang(Tianjin Medical University Cancer Institute and Hospital), Ji-Chang Meng(Bethune International Peace Hospital), Mei‐Ling Wang(Nanjing Forestry University), Nong Xu(First Affiliated Hospital Zhejiang University), YU Zhong-he(Qingdao University)
Cited by 0
Related Papers
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA
|Cell Research|2011|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
|Molecular Cancer|2020|1k
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
|Clinical Gastroenterology and Hepatology|2021|708